Telix Pharmaceuticals Limited has revealed a new partnership for its QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH and Quantinm AB based in Stockholm. QDOSE® is a validated software platform that allows accurate estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. Telix plans to integrate QDOSE® into its therapeutic radiopharmaceutical programs to develop personalized treatment regimens, potentially improving clinical outcomes while minimizing adverse effects on healthy organs and optimizing isotope supply chains.

QDOSE® supports dosimetry calculations using various imaging techniques and includes tools for attenuation and background correction. It will be integrated with Telix's artificial intelligence (AI) products, making it accessible to clinicians and other drug developers. QDOSE® has received regulatory clearance from both the FDA and CE marking for clinical use in the EU.

Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix, emphasized the importance of dosimetry analysis in nuclear medicine and the growing demand for personalized dosimetry in cancer care. He expressed confidence in QDOSE® becoming an industry standard in dosimetry analysis.

The agreement involves an arms’ length up-front transaction consideration, which is deemed non-material. Telix will pay undisclosed product royalties and fees on product sales as part of the partnership.

 

Source: globenewswire.com

Report Abuse